Bimekizumab is a monoclonal IgG1 antibody that selectively inhibits both interleukin-17A and interleukin-17F. The efficacy and safety of bimekizumab as compared with secukinumab, which selectively inhibits interleukin-17A alone, in patients […]
-
-
Can dermatology employers require employees to receive the COVID-19 vaccine?
-
THE 2020 VISION FOR NEMOLIZUMAB IN ATOPIC DERMATITIS
-
Expression of retinoid receptors in hand eczema.
-
S. aureus Agr Virulence Tied to Atopic Dermatitis in Infants
-
Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces.
